Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro

References

• Ward AB, Wilson IA. Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem Sci. 2015;40(2):101–107. doi:10.1016/j.tibs.2014.12.006
   PubMed Web of Science ®Google Scholar
• Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998;280(5371):1884–1888. doi:10.1126/science.280.5371.1884
   PubMed Web of Science ®Google Scholar
• Chen Y, Jin H, Tang X, et al. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect. 2022;11(1):30–49. doi:10.1080/22221751.2021.2011616
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Moore PL, Morris L. HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015;10(3):135–143. doi:10.1097/COH.0000000000000153
   PubMed Web of Science ®Google Scholar
• Cardozo-Ojeda EF, Perelson AS. Modeling HIV-1 within-host dynamics after passive infusion of the broadly neutralizing antibody VRC01. Front Immunol. 2021;12:710012. doi:10.3389/fimmu.2021.710012
   PubMed Web of Science ®Google Scholar
• Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 2016;352(6288):1001–1004. doi:10.1126/science.aaf1279
   PubMed Web of Science ®Google Scholar
• Malbec M, Porrot F, Rua R, et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med. 2013;210(13):2813–2821. doi:10.1084/jem.20131244
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li YX, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–861. doi:10.1126/science.1187659
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui P-Y, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–289. doi:10.1126/science.1178746
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–470. doi:10.1038/nature10373
   PubMed Web of Science ®Google Scholar
• Huang JH, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–412. doi:10.1038/nature11544
   PubMed Web of Science ®Google Scholar
• Hsu DC, Schuetz A, Imerbsin R, et al. TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathog. 2021;17:e1009339.
   PubMed Web of Science ®Google Scholar
• Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. 2014;15(7):445–451. doi:10.1038/nrg3742
   PubMed Web of Science ®Google Scholar
• Berns KI, Linden RM. The cryptic life style of adeno associated virus. BioEssays. 1995;17(3):237–245. doi:10.1002/bies.950170310
   PubMed Web of Science ®Google Scholar
• McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248–1254. doi:10.1038/sj.gt.3301514
   PubMed Web of Science ®Google Scholar
• Bartel MA, Weinstein JR, Schaffer DV. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther. 2012;19(6):694–700. doi:10.1038/gt.2012.20
   PubMed Web of Science ®Google Scholar
• Gardner MR. Promise and progress of an HIV-1 cure by adeno-associated virus vector delivery of anti-HIV-1 biologics. Front Cell Infect Microbiol. 2020;10:176. doi:10.3389/fcimb.2020.00176
   PubMed Web of Science ®Google Scholar
• Wagh K, Bhattacharya T, Williamson C, et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog. 2016;12(3):e1005520. doi:10.1371/journal.ppat.1005520
   PubMed Web of Science ®Google Scholar
• Yu YJ, Fu L, Jiang XY, et al. Expression of HIV-1 broadly neutralizing antibodies mediated by recombinant adeno-associated virus 8 in vitro and in vivo. Mol Immunol. 2016;80:68–77. doi:10.1016/j.molimm.2016.10.011
   PubMed Web of Science ®Google Scholar
• Balazs AB, Chen J, Hong CM, Rao DS, Yang LL, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481(7379):81–84. doi:10.1038/nature10660
   Web of Science ®Google Scholar
• Fang J, Qian JJ, Yi SL, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol. 2005;23(5):584–590. doi:10.1038/nbt1087
   PubMed Web of Science ®Google Scholar
• Wu XB, Dong XY, Wu ZJ, et al. A novel method for purification of recombinant adeno-associated virus vectors on a large scale. Chin Sci Bull. 2001;46(6):485–489. doi:10.1007/BF03187263
   Google Scholar
• Fu L, Li Y, Hu Y, et al. Norovirus P particle: an excellent vaccine platform for antibody production against Alzheimer’s disease. Immunol Lett. 2015;168(1):22–30. doi:10.1016/j.imlet.2015.09.002
   PubMed Web of Science ®Google Scholar
• Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods. 2002;106(1):81–88. doi:10.1016/S0166-0934(02)00138-6
   PubMed Web of Science ®Google Scholar
• Bi JP, Li FS, Zhang M, et al. An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses, Immunol. Lett. 2020;222:29–39.
   Google Scholar
• Daniel B, Juan JA, Hassibullah A, Tomas C, Joseph P, Daniel G. Generation of infectious recombinant Adeno-associated virus in Saccharomyces cerevisiae. PLoS One. 2017;12(3):e0173010.
   PubMed Web of Science ®Google Scholar
• Gao F, Weaver EA, Lu ZJ, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol. 2005;79(2):1154–1163. doi:10.1128/JVI.79.2.1154-1163.2005
   PubMed Web of Science ®Google Scholar
• Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296(5577):2354–2360. doi:10.1126/science.1070441
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010;236(1):265–275. doi:10.1111/j.1600-065X.2010.00910.x
   PubMedGoogle Scholar
• Ng CT, Jaworski JP, Jayaraman P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010;16(10):1117–1119. doi:10.1038/nm.2233
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019;25(4):547–553. doi:10.1038/s41591-019-0412-8
   PubMed Web of Science ®Google Scholar
• Mays LE, Wang L, Lin J, et al. AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther. 2014;22(1):28–41. doi:10.1038/mt.2013.134
   PubMed Web of Science ®Google Scholar
• Mueller C, Gernoux G, Gruntman AM, et al. 5 year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency. Mol Ther. 2017;25(6):1387–1394. doi:10.1016/j.ymthe.2017.03.029
   PubMed Web of Science ®Google Scholar
• Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002;99(18):11854–11859. doi:10.1073/pnas.182412299
   PubMed Web of Science ®Google Scholar
• Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–712. doi:10.1089/hum.2009.182
   PubMed Web of Science ®Google Scholar
• Li S, Qiao YB, Jiang S, Wang B, Kong W, Shan YM. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1. J Control Release. 2021;338:633–643. doi:10.1016/j.jconrel.2021.09.006
   PubMed Web of Science ®Google Scholar
• Mehandru S, Vcelar B, Wrin T, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol. 2007;81(20):11016–11031. doi:10.1128/JVI.01340-07
   PubMed Web of Science ®Google Scholar
• Kong R, Louder MK, Wagh K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015;89(5):2659–2671. doi:10.1128/JVI.03136-14
   PubMed Web of Science ®Google Scholar
• Florian K, Stromberg AH, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118–122. doi:10.1038/nature11604
   PubMed Web of Science ®Google Scholar
• Pejchala R, Walkerb LM, Stanfielda RL, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA. 2010;107(25):11483–11488. doi:10.1073/pnas.1004600107
   PubMed Web of Science ®Google Scholar